dr reddy's semaglutide Delhi High Court stops Dr. Reddy's from selling Ozempic-like drug after Novo Nordisk claims patent infringement. For More Details Visit: https://lawchakra.in/high-court/ozempic-drug-india-dr-reddys-novo-nordisk/ #delhihighcourt Dr Reddy's gets regulatory nod

The extra 30 seconds of verification costs nothing and protects everything

The fact that these benefits extend beyond glycemic control is further supported by the significant subgroup interaction observed for MI, suggesting that nondiabetic and obese patients may derive greater benefit from GLP-1 RA therapy compared with their diabetic or nonobese counterparts

Global, regional, and national burden of motor neuron diseases 19902016: a systematic analysis for the Global Burden of Disease Study 2016

Source: Polaris Market Research Analysis Regional Analysis The North America semaglutide market accounted for the largest share in 2024

Aranda-Rivera AK, Cruz-Gregorio A, Arancibia-Hernndez YL, Hernndez-Cruz EY, Pedraza-Chaverri J